ROSIGLITAZONE VS TELMISARTAN ON THE MODIFICATION OF INSULIN-RESISTANCE CKD

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 慢性肾脏疾病(CKD)的患病率正以惊人的速度增长，发现包括胰岛素抵抗在内的常见并发症的发生对于我们预测发病率和死亡率以及更有效地治疗患者的能力至关重要。胰岛素抵抗与心血管危险因素的发展有关，包括高血压、血脂异常、炎症，甚至可能加速CKD的进展。这些早期肾脏疾病的危险因素值得进行一项潜在干预措施的试点研究，以逆转胰岛素抵抗。肾脏疾病预后质量倡议(K-DOQI)中没有具体的指南来解决慢性肾脏病引起的胰岛素抵抗的治疗问题。TZD治疗或新型血管紧张素II受体阻滞剂替米沙坦可逆转CKD患者的胰岛素抵抗，为长期治疗减轻CKD的并发症和预后提供了依据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The prevalence of chronic kidney disease (CKD) is growing at an alarming rate and discovering when common complications develop including insulin resistance is critical to our ability to anticipate morbidity and mortality and treat patients more effectively. Insulin resistance has been associated with the development of cardiovascular risk factors including hypertension, dyslipidemia, inflammation and perhaps accelerated progression of CKD. Such risk factors in the setting of early renal disease merit a pilot study of a potential intervention to reverse insulin resistance. There are no specific guidelines included in Kidney Disease Outcome Quality Initiative (K-DOQI) that address treatment of insulin resistance due to CKD. The demonstration that thiazolidinedione (TZD) therapy or that telmisartan, an angiotensin II receptor blocker with novel properties, reverses insulin resistance in CKD could provide a basis for long-term therapy that attenuates the complications and prognosis of CKD.